Cost effectiveness of the interferon-γ release assay for tuberculosis screening of hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 28, Issue 3, 2013, Pages 682-688

  Kowada, Akiko ^a  

^a Ota City Public Health Office   (Japan)

Author keywords

Cost effectiveness; Hemodialysis; Interferon release assay; Tuberculin skin test; Tuberculosis screening

Indexed keywords

ISONIAZID;

ARTICLE; BCG VACCINATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEMODIALYSIS PATIENT; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; RADIOGRAPHY, THORACIC; RENAL DIALYSIS; TUBERCULIN TEST; TUBERCULOSIS; X-RAYS;

EID: 84874817331     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs479     Document Type: Article

References (37)

1. Hoffmann M, Tsinalis D, Vernazza P et al. Assessment of an interferon- gamma release assay for the diagnosis of latent tuberculosis infection in haemodialysis patient. Swiss Med Wkly 2010; 140: 286-292
2. Maden E, Bekci TT, Kesli R et al. Evaluation of performance of quantiferon assay and tuberculin skin test in end stage renal disease patients receiving hemodialysis. New Microbiol 2011; 34: 351-356
3. Inoue T, Nakamura T, Katsuma A et al. The value of QuantiFERON TB-Gold in the diagnosis of tuberculosis among dialysis patients. Nephrol Dial Transplant 2009; 24: 2252-2257
4. Lee SS, Chou KJ, Su IJ et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection 2009; 37: 96-102
5. Winthrop KL, Nyendak M, Calvet H et al. Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 2008; 3: 1357-1363
6. Passalent L, Khan K, Richardson R et al. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2007; 2: 68-73
7. Richardson RM. The diagnosis of tuberculosis in dialysis patients. Semin Dial 2012; 25: 419-422
8. Seyhan EC, Sökücü S, Altin S et al. Comparison of the Quanti- FERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection in hemodialysis patients. Transpl Infect Dis 2010; 12: 98-105
9. Jensen PA, Lambert LA, Iademarco MF et al.; CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54(RR- 17): 1-141
10. Hoogewerf M, Boland GJ, Hoepelman AI et al. No influence of haemodialysis on interferon production in the QuantiFERONTB Gold-In-Tube test. J Nephrol 2011; 24: 625-630
11. Kowada A. Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening. Mol Diagn Ther 2012; 16: 181-190
12. Kowada A, Takahashi O, Shimbo T et al. Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 2008; 12: 235-251
13. Kowada A, Deshpande GA, Takahashi O et al. Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations. Mol Diagn Ther 2010; 14: 229-236
14. Kowada A, Deshpande GA, Takahashi O et al. Cost-effectiveness analysis of interferon-γ release assays versus chest X-ray for annual tuberculosis screening of healthcare workers. J Hosp Infec 2011; 78: 152-154
15. Kowada A. Cost-effectiveness of interferon-γ release assay versus chest X-ray for tuberculosis screening of employees. Am J Infect Control 2011; 39: e67-e72
16. Kowada A. Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-α antagonist therapy. Mol Diagn Ther 2010; 14: 367-373
17. Japanese Society for Dialysis Therapy. Dialysis patients data in Japan [in Japanese] [online], 2011. URL: http://docs.jsdt.or.jp/ overviewl (1 September 2012, date last accessed)
18. 2011 USRDS ANNUAL. Data report [online]. www.usrds.org/ 2011/view/v2-05.asp (1 September 2012, date last accessed)
19. Klote MM, Agodoa LY, Abbott KC. Risk factors for Mycobacterium tuberculosis in US chronic dialysis patients. Nephrol Dial Transplant 2006; 21: 3287-3292
20. Horsburgh CR, Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067
21. Segall L, Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 2010; 5: 1114-1122
22. Yoshiyama T. Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings. Kekkaku 2000; 75: 629-641 [in Japanese]
23. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564
24. Vikrant S, Agarwal SK, Gupta S et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 2005; 7: 99-108
25. Triverio PA, Bridevaux PO, Roux-Lombard P et al. Interferongamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant 2009; 24: 1952-1956
26. Tuberculosis Research Committee (Ryoken). Relapse rate of tuberculosis treated with standard regimen of chemotherapy [in Japanese]. Kekkaku 2009; 84: 617-625
27. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a meta-analysis. Chest 2010; 137: 952-968
28. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184
29. Tattevin P, Casalino E, Fleury L et al. The validity of medical history, classic symptoms, and chest radiographs in predicting pulmonary tuberculosis: derivation of a pulmonary tuberculosis prediction model. Chest 1999; 115: 1248-1253
30. Cohen R, Muzaffar S, Capellan J et al. The validity of classic symptoms and chest radiographic configuration in predicting pulmonary tuberculosis. Chest 1996; 109: 420-423
31. Igakutsushin-sya. Medical Insurance Reimbursement Table in Japan [in Japanese]. Tokyo: Igakutsushin-sya, 2010
32. Ministry of Health, Labor and Welfare. Basic survey on wage structure [online]. http://www.mhlw.go.jp/english/database/db-l/ ordinary.html (1 September 2012, date last accessed)
33. Research Institute of Tuberculosis. Tuberculosis Surveillance 2009 [in Japanese] [online]. Tokyo: Research Institute of Tuberculosis, 2009. http://jata.or.jp/rit/ekigaku/ (1 September 2012, date last accessed)
34. Takayama N, Sakiyama H, Okabe N et al. Cumulative national immunization rate of BCG vaccine in Japan. J Jpn Med Assoc 2009; 137; 2132-2136 [in Japanese]
35. Tsevat J, Taylor WC, Wong JB et al. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis 1988; 137: 215-220
36. Laupacis A, Keown P, Pus N et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-242
37. Chee CB, KhinMar KW, Gan SH et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010; 36: 355-361